港股异动 | 药明合联(02268)盘中涨超8% 公司有望持续受益XDC CRDMO行业下游需求改善趋势

Core Viewpoint - WuXi AppTec (02268) has seen a significant stock price increase, with a rise of over 8% during trading, currently up 6.6% at HKD 62.2, with a trading volume of HKD 253 million. The company has issued a positive earnings forecast for 2025, indicating strong growth potential in the coming years [1]. Group 1: Earnings Forecast and Adjustments - WuXi AppTec has released an earnings forecast for 2025, prompting CMB International to slightly adjust its revenue and adjusted net profit predictions for 2025-2027 down by 1-3%, estimating revenues of RMB 5.88 billion, 8.28 billion, and 11.11 billion for the respective years, and adjusted net profits of RMB 1.6 billion, 2.45 billion, and 3.42 billion [1]. - The projected compound annual growth rate (CAGR) for revenues from 2025 to 2027 is strong at 38% and 46%, primarily driven by rapid growth in comprehensive CMC orders, particularly from late-stage clinical and commercialization orders [1]. Group 2: Market Trends and Opportunities - In the first two months of 2026, there were 25 financing events in the global XDC sector, a significant increase from 18 events in the same period of 2025, indicating a growing trend in investment activity [1]. - The number of BD transactions for XDC candidate drugs has remained stable, with a substantial increase in total upfront payments, reflecting a robust market environment [1]. - Since the beginning of 2024, there has been a gradual increase in the number of financing events, BD transactions, and total upfront payments in the XDC field, suggesting a sustained demand improvement in the XDC CRDMO industry [1]. - WuXi AppTec, as a leading company with strong technical capabilities and integrated delivery capabilities, is well-positioned to benefit from these trends and expand its market share [1].